• Rapid ART - (09/17/20)
   
  
• Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials - (09/16/20)
   
  
• EDITORIAL: Is Modern Antiretroviral Therapy Causing Weight Gain? - (09/16/20)
   
  
• (Vascepa) Final EVAPORATE Results for Vascepa Raise Eyebrows - (09/16/20)
   
  
• ADHOC Aging-HIV Database Community Call Today Sept 3 2020 - (09/16/20)
   
  
• Sexual transmission of an extensively drug-resistant HIV-1 strain - (09/16/20)
   
  
• Cardiovascular disease risk among transgender women living with HIV in the United States - (09/16/20)
   
  
• Risk of Cataract Surgery in HIV-Infected Individuals: A Danish Nationwide Population-Based Cohort Study - (08/25/20)
   
  
• New HIV ART & Long-Acting Drugs - (08/25/20)
   
  
• CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY - (08/25/20)
   
  
More HIV Articles...
 

• UNAIDS Press release - COVID-19 could affect the availability and cost of antiretroviral medicines, but the risks can be mitigated - (06/25/20)
   
  
• UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV - (06/24/20)
   
  
• Coronavirus puts drug repurposing on the fast track - (03/02/20)
   
  
• FDA Expands Coronavirus Testing in the United States - (03/02/20)
   
  
More News Updates Articles...
 

• HCV & HCV/HIV Coinfection Micro-Elimination Grants: funding for 30+ projects - -
   
  
• EASL: Summary from EASL 2018 for Hepatitis C (HCV) HCV in 2018: Success stories and remaining challenges? - Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany-
   
  
• EASL: HCV Micro-Elimination Funding Grants Available
   
  
• Reply to: "Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action" - (09/17/20)
   
  
• Optimal Non-Invasive Screening Strategy for Nonalcoholic Fatty Liver Disease in a Prospective Cohort of Patients with Type 2 Diabetes - (09/17/20)
   
  
• Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion - (09/17/20)
   
  
• Impact of Pre-existing Chronic Liver Disease on the Outcome of Patients with COVID-19 Disease - comment - (09/17/20)
   
  
• Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study - (09/17/20)
   
  
• Donor and transplant candidate selection for solid organ transplantation during the COVID‐19 pandemic - (09/17/20)
   
  
More Hep C Articles...
 

• EASL: Better Survival With TDF Than Entecavir After Hepatectomy for HCC: "Tenofovir vs entecavir on post-operative recurrence-free and overall survival of patients with hepatitis B virus-related hepatocellular carcinoma" - Mark Mascolini (09/16/20)
   
  
• EASL: Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Renal Impairment: Week-48 Results From a Phase 2 Open-label Study - (09/16/20)
   
  
More Hep B Articles...
 

List not necessarily listed here in order of date being held.